SBIR/STTR Research Award
Expression System and Process Development for MIS Scale Up
Award amount
$224,915Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- NEMUCORE MEDICAL INNOVATIONS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- XJFVQ8JVRED5
- Solicitation number
- PA13-234
- Topic code
- NCI
Research abstract
DESCRIPTION (provided by applicant): Ovarian cancer is a highly lethal gynecologic cancer with an estimated 21,860 new cases and approximately 13,850 deaths in the USA per year. A large majority of the patients, cancer reoccurs after initial treatment and manifest resistance to conventional and novel chemotherapeutic agents representing a formidable clinical challenge, which could be mitigated by the production of novel, targeted therapies. Recently, Drs. Donahoe, MacLaughlin and Teixeira from Massachusetts General Hospital (MGH) showed that recombinant human M?llerian Inhibiting Substance (rhMIS) specifically targets ovarian cancer cell populations that respond poorly to the currently used chemotherapeutic agents and could be an innovative, targeted medicine to address recurrent multidrug resistant ovarian cancer. In vivo when MIS was tested as a single agent it was found to inhibit tumor growth in experiments lasting 80 to 100 days. Additionally since the MIS receptor is poorly expressed in endogenou
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Modified MIS Production & Process Development for Preclinical & Clinical Studies
- Targeted Docetaxel-Nanocolloid for the Treatment of Ovarian Cancer
- EGFR-Targeted Nanoemulsions for Imaging and Therapy of Ovarian Cancer
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
4 SBIR/STTR records share this UEI (2010–2015). Reported award amounts total $1,040,678. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services